216 GSK Annual Report 2011 Financial Financial statements of GlaxoSmithKline plc statements prepared under UK GAAP Directors statement of responsibilities in relation to Disclosure of information to auditors the companys financial statements The Directors in ofce at the date of this Report have each confirmed that: The Directors are responsible for preparing the parent company, GlaxoSmithKline plc, financial statements and the Remuneration s SO FAR AS HE OR SHE IS AWARE THERE IS NO RELEVANT AUDIT Report in accordance with applicable law and regulations.
information of which the companys auditors are unaware: and Company law requires the Directors to prepare financial s HE OR SHE HAS TAKEN ALL THE STEPS THAT HE OR SHE OUGHT TO HAVE statements for each financial year.
Under that law the Directors taken as a Director to make himself or herself aware of any have elected to prepare the parent company financial statements relevant audit information and to establish that the companys in accordance with United Kingdom Accounting Standards and auditors are aware of that information.
applicable law United Kingdom Generally Accepted Accounting This conrmation is given and should be interpreted in accordance Practice.
Under company law the Directors must not approve the with the provisions of Section 418 of the Companies Act 2006. parent company financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Going concern basis company for that period.
After making enquiries, the Directors have a reasonable In preparing those financial statements, the Directors are expectation that the company has adequate resources to continue required to: in operational existence for the foreseeable future.
For this reason, they continue to adopt the going concern basis in preparing the s SELECT SUITABLE ACCOUNTING POLICIES AND THEN APPLY financial statements.
them consistently: The UK Corporate Governance Code s MAKE JUDGEMENTS AND ACCOUNTING ESTIMATES THAT ARE reasonable and prudent: The Board considers that GlaxoSmithKline plc applies the principles and provisions of the UK Corporate Governance Code s STATE WITH REGARD TO THE PARENT COMPANY lNANCIAL STATEMENTS maintained by the Financial Reporting Council, as described in that applicable UK Accounting Standards have been followed, the Corporate Governance section on pages 82 to 105, and has subject to any material departures disclosed and explained in complied with its provisions except as disclosed on page 84.
As the parent company financial statements.
required by the Financial Services Authoritys Listing Rules, the The Directors are responsible for keeping adequate accounting auditors have considered the Directors statement of compliance records that are sufficient to show and explain the companys in relation to those points of the UK Corporate Goverance Code transactions and disclose with reasonable accuracy at any time which are specified for their review.
the financial position of the company and to enable them to ensure that the parent company financial statements and Remuneration Report comply with the Companies Act 2006.
They are also responsible for safeguarding the assets of the Sir Christopher Gent company and hence for taking reasonable steps for the Chairman prevention and detection of fraud and other irregularities.
9 March 2012 The parent company financial statements for the year ended 31 December 2011, comprising the balance sheet for the year ended 31 December 2011 and supporting notes, are set out on pages 218 to 221 of this report.
The responsibilities of the auditors in relation to the parent company financial statements are set out in the Independent Auditors report on page 217.
The financial statements for the year ended 31 December 2011 are included in the Annual Report, which is published in hardcopy printed form and made available on our website.
The Directors are responsible for the maintenance and integrity of the Annual Report on our website in accordance with UK legislation governing the preparation and dissemination of financial statements.
Access to the website is available from outside the UK, where comparable legislation may be different.
GSK Annual Report 2011 217 Overview 02 Strategic review 10 Financial review & risk 51 Governance & remuneration 78 Financial statements 134 Shareholder information 222 Opinion on other matters prescribed by the Companies Independent Auditors report Act 2006 to the members of GlaxoSmithKline plc In our opinion: We have audited the parent company financial statements of s THE PART OF THE $IRECTORS 2EMUNERATION 2EPORT TO BE AUDITED GlaxoSmithKline plc for the year ended 31 December 2011 has been properly prepared in accordance with the Companies which comprise the Company Balance Sheet UK GAAP and the Act 2006: and related Notes A-H.
The financial reporting framework that has been applied in their preparation is applicable law and United s THE INFORMATION GIVEN IN THE $IRECTORS 2EPORT FOR THE lNANCIAL Kingdom Accounting Standards United Kingdom Generally year for which the parent company financial statements are Accepted Accounting Practice.
prepared is consistent with the parent company financial statements.
Respective responsibilities of directors and auditors Matters on which we are required to report As explained more fully in the Directors statement of by exception responsibilities set out on page 216, the directors are responsible for the preparation of the parent company financial statements We have nothing to report in respect of the following matters and for being satisfied that they give a true and fair view.
where the Companies Act 2006 requires us to report to you if, Our responsibility is to audit and express an opinion on the in our opinion: parent company financial statements in accordance with s ADEQUATE ACCOUNTING RECORDS HAVE NOT BEEN KEPT BY THE PARENT applicable law and International Standards on Auditing UK and company, or returns adequate for our audit have not been Ireland.
Those standards require us to comply with the Auditing received from branches not visited by us: or Practices Boards Ethical Standards for Auditors.
s THE PARENT COMPANY lNANCIAL STATEMENTS AND THE PART OF THE This report, including the opinions, has been prepared for and Directors Remuneration Report to be audited are not in only for the companys members as a body in accordance with agreement with the accounting records and returns: or Chapter 3 of Part 16 of the Companies Act 2006 and for no other purpose.
We do not, in giving these opinions, accept or assume s CERTAIN DISCLOSURES OF DIRECTORS REMUNERATION SPECIlED BY LAW responsibility for any other purpose or to any other person to are not made: or whom this report is shown or into whose hands it may come save s WE HAVE NOT RECEIVED ALL THE INFORMATION AND EXPLANATIONS WE where expressly agreed by our prior consent in writing.
Scope of the audit of the financial statements Other matters An audit involves obtaining evidence about the amounts and We have reported separately on the Group financial statements of disclosures in the financial statements sufficient to give reasonable GlaxoSmithKline plc for the year ended 31 December 2011. assurance that the financial statements are free from material misstatement, whether caused by fraud or error.
This includes an The Company has passed a resolution in accordance with section assessment of: whether the accounting policies are appropriate to 506 of the Companies Act 2006 that the senior statutory the parent companys circumstances and have been consistently auditors name should not be stated.
applied and adequately disclosed: the reasonableness of significant accounting estimates made by the directors: and the overall presentation of the financial statements.
In addition, we read all the financial and non-financial information in the  LLP annual report to identify material inconsistencies with the audited Chartered Accountants and Statutory Auditors financial statements.
If we become aware of any apparent London material misstatements or inconsistencies we consider the 9 March 2012 implications for our report.
Opinion on financial statements In our opinion the parent company financial statements: s GI five A TRUE AND FAIR VIEW OF THE STATE OF THE COMPANY S AFFAIRS as at 31 December 2011: s HAVE BEEN PROPERLY PREPARED IN ACCORDANCE WITH 5NITED Kingdom Generally Accepted Accounting Practice: and s HAVE BEEN PREPARED IN ACCORDANCE WITH THE REQUIREMENTS OF the Companies Act 2006.
218 GSK Annual Report 2011 Financial Financial statements of GlaxoSmithKline plc statements prepared under UK GAAP Company balance sheet UK GAAP at 31 December 2011 2011 2010 Notes m m Fixed assets investments D 19,680 19,659 Debtors E 3,870 720 Cash at bank 19 10 Current assets 3,889 730 Creditors: amounts due within one year F 481 6,230 Net current assets liabilities 3,408 5,500 Net assets 23,088 14,159 Capital and reserves Called up share capital G 1,387 1,418 Share premium account G 1,673 1,428 Other reserves H 1,339 1,282 Profit and loss account H 18,689 10,031 Equity shareholders funds 23,088 14,159 Approved by the Board on 9 March 2012.
Sir Christopher Gent Chairman GlaxoSmithKline plc Registered number: 3888792 GSK Annual Report 2011 219 Overview 02 Strategic review 10 Financial review & risk 51 Governance & remuneration 78 Financial statements 134 Shareholder information 222 Expenditure Notes to the company balance sheet UK GAAP Expenditure is recognised in respect of goods and services received when supplied in accordance with contractual terms.
A Presentation of the financial statements Provision is made when an obligation exists for a future liability in respect of a past event and where the amount of the obligation Description of business can be reliably estimated.
GlaxoSmithKline plc is the parent company of GSK, a major global healthcare group which is engaged in the creation and discovery, Investments in subsidiary companies development, manufacture and marketing of pharmaceutical Investments in subsidiary companies are held at cost less any products, including vaccines, over-the-counter OTC medicines provision for impairment.
Impairment of investments Preparation of financial statements The carrying value of investments are reviewed for impairment The financial statements, which are prepared on a going concern when there is an indication that the investment might be basis, are drawn up in accordance with UK generally accepted impaired.
Any provision resulting from an impairment review is accounting principles UK GAAP and with UK accounting charged to the income statement in the year concerned.
presentation as at 31 December 2011, with comparative gures Share based payments as at 31 December 2010.
Where appropriate, comparative gures are reclassied to ensure a consistent presentation with The issuance by the company to its subsidiaries of a grant over the current year information.
companys options, represents additional capital contributions by the company in its subsidiaries.
An additional investment in As permitted by s. 408 of the Companies Act 2006, the profit and subsidiaries results in a corresponding increase in shareholders loss account of the company is not presented in this Annual Report.
The additional capital contribution is based on the fair Accounting convention and standards value of the grant issued, allocated over the underlying grants vesting period.
The balance sheet has been prepared using the historical cost convention and complies with applicable UK accounting Taxation standards.
Current tax is provided at the amounts expected to be paid Accounting principles and policies applying tax rates that have been enacted or substantially enacted by the balance sheet date.
The preparation of the balance sheet in conformity with generally accepted accounting principles requires management to make The company accounts for taxation which is deferred or estimates and assumptions that affect the reported amounts of accelerated by reason of timing differences which have originated assets and liabilities and disclosure of contingent assets and but not reversed by the balance sheet date.
Deferred tax assets liabilities at the date of the balance sheet.
Actual amounts could are only recognised to the extent that they are considered differ from those estimates.
recoverable against future taxable profits.
The balance sheet has been prepared in accordance with the Deferred tax is measured at the average tax rates that are companys accounting policies approved by the Board and expected to apply in the periods in which the timing differences described in Note B. are expected to reverse.
Deferred tax liabilities and assets are not discounted.
B Accounting policies Financial guarantees Foreign currency transactions Liabilities relating to guarantees issued by the company on behalf Foreign currency transactions are recorded at the exchange rate of its subsidiaries are initially recognised at fair value and ruling on the date of transaction, or at the forward rate if hedged amortised over the life of the guarantee.
Foreign currency assets and liabilities are translated at rates of exchange ruling at the balance C Operating profit sheet date, or at the forward rate.
A fee of 11,474 2010 11,140 relating to the audit of the Dividends paid and received company has been charged in operating profit.
Dividends paid and received are included in the accounts in the period in which the related dividends are actually paid or received.
220 GSK Annual Report 2011 Financial Financial statements of GlaxoSmithKline plc statements prepared under UK GAAP Notes to the company balance sheet UK GAAP continued D Fixed assets 2011 2010 m m Shares in GlaxoSmithKline Services Unlimited 613 613 Shares in GlaxoSmithKline Holdings One Limited 18 18 Shares in GlaxoSmithKline Holdings Limited 17,888 17,888 Shares in GlaxoSmithKline Mercury Limited 33 33 18,552 18,552 Capital contribution relating to share based payments 1,128 1,107 19,680 19,659 E Debtors 2011 2010 m m Amounts due within one year: UK Corporation tax recoverable 227 223 Amounts owed by Group undertakings 3,236 112 3,463 335 Amounts due after more than one year: Amounts owed by Group undertakings 407 385 3,870 720 F Creditors 2011 2010 m m Amounts due within one year: Bank overdraft 9 9 Amounts owed to Group undertakings 4 5,774 Other creditors 468 447 481 6,230 The company has guaranteed debt issued by one of its subsidiary companies for which it receives an annual fee from the subsidiary.
In aggregate, the company has outstanding guarantees over $10 billion of debt instruments.
The amount due from the subsidiary companies in relation to these guarantee fees will be recovered over the life of the bonds and are disclosed within debtors see Note E. GSK Annual Report 2011 221 Overview 02 Strategic review 10 Financial review & risk 51 Governance & remuneration 78 Financial statements 134 Shareholder information 222 Notes to the company balance sheet UK GAAP continued G Share capital and share premium account Share Ordinary Shares of 25p each premium Number m m Share capital authorised At 31 December 2010 10,000,000,000 2,500 At 31 December 2011 10,000,000,000 2,500 Share capital issued and fully paid At 1 January 2010 5,665,128,719 1,416 1,368 Issued under employee share schemes 5,329,458 2 60 At 31 December 2010 5,670,458,177 1,418 1,428 Issued under employee share schemes 21,949,144 5 245 Share capital purchased and cancelled 142,204,223 36 At 31 December 2011 5,550,203,098 1,387 1,673 31 December 31 December 2011 2010 000 000 Number of shares issuable under outstanding options 126,810 207,132 Number of unissued shares not under option 4,322,987 4,122,410 At 31 December 2011, of the issued share capital, 90,922,720 shares were held in the ESOP Trusts, 501,157,927 shares were held as Treasury shares and 4,958,122,451 shares were in free issue.
All issued shares are fully paid.
The nominal, carrying and market values of the shares held in the ESOP Trusts are disclosed in Note 42, Employee share schemes.
A total of 169 million shares were purchased by the company during 2011 at a cost of 2,191 million.
During the year 142 million shares were cancelled and 27 million shares added to Treasury shares.
The company expects to make further share repurchases of 12 billion during 2012.
The exact amount and timing of further purchases and whether the shares will be held as Treasury shares or be cancelled will be determined by the company and is dependent on market conditions and other factors.
No shares were purchased in the period 1 January 2012 to 7 February 2012.
In the period 8 February 2012 to 2 March 2012 8.6 million shares were purchased at a cost of 122.3 million.
H Reserves Other profit and reserves loss account Total m m m At 1 January 2010 1,255 13,270 14,525 Loss attributable to shareholders 34 34 Dividends to shareholders 3,205 3,205 Capital contribution relating to share based payments 27 27 At 31 December 2010 1,282 10,031 11,313 Profit attributable to shareholders 14,255 14,255 Dividends to shareholders 3,406 3,406 Shares purchased and cancelled or held as Treasury share 36 2,191 2,155 Capital contribution relating to share based payments 21 21 At 31 December 2011 1,339 18,689 20,028 The profit of GlaxoSmithKline plc for the year was 14,255 million 2010 loss of 34 million, which after dividends of 3,406 million 2010 3,205 million, gave a retained profit of 10,849 million 2010 loss of 3,239 million.
After the cost of shares purchased and cancelled or held as Treasury shares of 2,191 million 2010 nil, the profit and loss account reserve at 31 December 2011 stood at 18,689 million 2010 10,031 million, of which 4,096 million is unrealised 2010 4,096 million.
